Shots:

• The P-III JADE MONO-2 study involves assessing of Abrocitinib (qd- 100mg & 200mg) vs PBO in 391 patients with mod. to sev. AD aged ≥12yrs. for 12wks.
• The P-III JADE MONO-2 study results: met its 1EPs & 2EPs i.e- improvement in IGA score of clear (0) or almost clear (1) skin- ≥75% change in baseline in EASI score & 4point or larger reduction in itching measured with a decrease in magnitude in PSAAD respectively- safety results are consistent with JADE MONO-1 study
• Abrocitinib is an oral JAK-inhibitor- modulating multiple cytokines involved in the pathophysiology of AD- including IL-4- IL-13- IL-31- and interferon-gamma and has received FDA’s BT designation in Feb’2018

Ref: Pfizer | Image: Pharmaceutical Technology

Click here to­ read full press release/ article